BioMedNewsBreaks Archive - Page 4 of 253

TuesdayFeb 17, 2026 10:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Featured on Latest BioMedWire Podcast by IBN

Earth Science Tech (OTC: ETST) was featured on the latest episode of The BioMedWire Podcast released by IBN, with Chairman and CEO Giorgio R. Saumat outlining the company’s vertically integrated healthcare model spanning telehealth and compounding pharmaceuticals, its cash-flow-positive operations and strong balance sheet, and preparations for a potential uplist. During the interview, Saumat highlighted the company’s profitability, limited debt and 2025 diversification initiatives, as Earth Science Tech positions to scale operations in 2026 while IBN continues expanding its specialized content distribution platform. To view the full press release, visit https://ibn.fm/iSd01 About Earth Science Tech, Inc. Earth Science Tech, Inc.…

TuesdayFeb 17, 2026 9:30 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models

Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is iron-dependent and linked to the drug’s proposed intracellular metal-modulating mechanism. The company said supplemental iron significantly attenuated tumor cell mortality, supporting that Telomir-Zn reduces labile redox-active iron while increasing zinc availability, targeting the elevated iron levels and oxidative stress observed in many triple-negative breast cancer tumors. To view the full press release, visit https://ibn.fm/CHKT9 About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing…

TuesdayFeb 17, 2026 9:26 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products

Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband’s AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter abuse, diversion and misuse of drugs with abuse potential, supported by a broad international patent portfolio. To view the full press release, visit https://ibn.fm/2YOl8 About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch…

ThursdayFeb 12, 2026 10:50 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line data from the Phase 3 FLASH2 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma expected in the second half of 2026, with an interim analysis approaching in the second quarter and 66 of 80 patients enrolled as of Feb. 10. The letter also reviewed positive Phase 2a data for SGX945 (dusquetide) in Behçet’s Disease published in Rheumatology (Oxford), encouraging Phase 2a psoriasis results for SGX302, ongoing strategic evaluations including partnership and M&A opportunities, and the company’s…

ThursdayFeb 12, 2026 10:39 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a proprietary TGF-β antisense therapeutic platform, with allowed patent claims in Australia covering OT-101 (SEQ ID NO:9) for the treatment of Parkinson’s Disease, including associated sleep-related symptoms, and granted utility model patents in China and Germany for an intracranial continuous infusion delivery device. The company stated the expanded protection spans therapeutic use claims, CNS delivery methods, device-enabled administration and broader oncology and neurology applications, forming an integrated commercialization platform intended to strengthen long-term defensibility, support strategic partnerships and enhance shareholder value, with additional data presentations planned…

ThursdayFeb 12, 2026 9:20 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation for NV-387 as a treatment for MPox with the U.S. FDA Office of Orphan Products Development. If granted, the designation would provide incentives including tax credits for qualified clinical trials, exemption from certain user fees and potential seven years of market exclusivity following approval. The company highlighted ongoing global MPox concerns, limited therapeutic options and challenges associated with existing smallpox antivirals such as TPOXX(R) and TEMBEXA(R), noting continued viral mutations and the need for an effective therapeutic solution. To view the full press release, visit…

WednesdayFeb 11, 2026 2:51 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications,” reads a recent article. “At the center of LIXTE’s strategy is protein phosphatase 2A, or PP2A, an enzyme that plays a critical role in regulating cell growth, DNA repair, and survival signaling. In many cancers, PP2A activity enables tumor cells to recover from the damage caused by treatment,…

TuesdayFeb 10, 2026 9:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) to Report Fourth-Quarter 2025 Financial Results Feb. 17

Earth Science Tech (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential operating businesses, announced that it will report financial results for the three months ended Dec. 31, 2025, after the close of trading on Tuesday, Feb. 17, 2026. To view the full press release, visit https://ibn.fm/FnUf9 About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. is a diversified holding company focused on the health and wellness sector. Through its wholly-owned subsidiaries, ETST operates a vertically integrated portfolio that includes high-quality compounding pharmacies, telemedicine platforms, and targeted healthcare facilities. The Company currently owns RxCompoundStore.com and Mister…

MondayFeb 09, 2026 9:10 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using proprietary intranasal delivery technology, today outlined targeted milestones for 2026 as it advances ONP-002, a novel intranasal neurosteroid, toward Phase 2 clinical development. The Company is preparing to initiate a Phase 2a clinical trial of ONP-002 in Australia for the treatment of concussion and mild traumatic brain injury (mTBI), positioning the candidate as a potential first-in-class pharmacological therapy for a large and underserved global market following positive preclinical and Phase 1 safety and efficacy results. To view the full press release, visit https://ibn.fm/s5NeN About Oragenics, Inc. Oragenics, Inc.…

ThursdayFeb 05, 2026 9:20 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug ("IND") application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, to be conducted by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The dose-expansion study is expected to enroll up to 45 colorectal cancer patients who have completed standard curative-intent therapy and test positive for circulating tumor DNA ("ctDNA"), a marker associated with minimal residual disease ("MRD") and cancer recurrence, with the trial planned to begin in the first half of 2026 under the leadership of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Featured on Latest BioMedWire Podcast by IBN

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Iron-Dependent Tumor Cell Mortality in TNBC Models

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Exclusive Costa Rica Distribution Deal for AVERSA Fentanyl and Sports Tape Products

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) to Report Fourth-Quarter 2025 Financial Results Feb. 17

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search